Safety of quadrivalent human papillomavirus vaccine (Gardasil®) in pregnancy: Adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013

Vaccine

Volumn 33, Issue 4, 2015, Pages 519-522

  Moro, Pedro L ^a   Zheteyeva, Yenlik ^b   Lewis, Paige ^a   Shi, Jing ^c   Yue, Xin ^d   Museru, Oidda I ^a   Broder, Karen ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Adverse events; Epidemiology; Pregnancy; Quadrivalent human papillomavirus vaccine; Surveillance; Vaccine safety

Indexed keywords

HEPATITIS A VACCINE; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18;

ABDOMINAL PAIN; ARTICLE; BIRTH DEFECT; BREECH PRESENTATION; CONDYLOMA ACUMINATUM; DOWN SYNDROME; DRUG FEVER; DRUG SAFETY; DYSPNEA; FAINTNESS; FEMALE; GASTROENTERITIS; HUMAN; JAUNDICE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NAUSEA; OLIGOHYDRAMNIOS; PREGNANT WOMAN; PRURITUS; PULMONARY VENOUS RETURN; RESPIRATORY TRACT DISEASE; SPONTANEOUS ABORTION; STILLBIRTH; TESTIS TORSION; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VAGINA BLEEDING; VOMITING; ADOLESCENT; ADULT; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; NEWBORN; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PREGNANCY; PREGNANCY OUTCOME; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFANT, NEWBORN; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREGNANCY; PREGNANCY OUTCOME; YOUNG ADULT;

EID: 84920599766     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.11.047     Document Type: Article

References (19)

1. Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, 18] vaccine, recombinant): product information and supporting documents. Food and Drug Administration. Available from: [accessed 01.10.13]. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094042.htm.
2. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R., Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP) Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56(RR-2):1-24. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm [accessed 01.10.13].
3. Merck & Co., Inc. Pregnancy Registry for GARDASIL. Available from: [accessed 20.03.14]. http://www.merckpregnancyregistries.com/gardasil.html.
4. ®): exposure during pregnancy June 1, 2006 through May 31, 2012. Meeting of the Advisory Committee on Immunization Practices (ACIP) 2013, Available from: http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-jun-2013/02-HPV-Lievano.pdf [accessed 05.03.14].
5. Varricchio F., Iskander J., DeStefano F. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004, (23):287-294.
6. Chen R.T., Rastogi S.C., Mullen J.R., Hayes S.W., Cochi S.L., Donlon J.A., et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 1994, 12:542-550.
7. Medical dictionary for regulatory activities maintenance and support services organization 2010, http://www.meddramsso.com/index.asp.
8. Food and Drug Administration 21 Code of Federal Regulation Part 600.80. Postmarketing reporting of adverse experiences. Federal Regist 1997, 62:52252-52253. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=600.80 [accessed 01.10.13].
9. Moro P.L., Broder K., Zheteyeva Y., Walton K., Rohan P., Sutherland A., et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. Am J Obstet Gynecol 2011, 204:e1-e7.
10. Vellozzi C., Broder K.R., Haber P., Guh A., Nguyen M., Cano M., et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010, 28:7248-7255.
11. Prenatal care. Williams obstetrics 2010, 189-214. McGraw-Hill Companies, Inc., New York. G. Cunningham, K.J. Leveno, S.L. Bloom, J.C. Hauth, D.J. Rouse, C.Y. Spong (Eds.).
12. Moro P.L., Museru O.I., Niu M., Lewis P., Broder K. Reports to the Vaccine Adverse Event Reporting System after hepatitis A and hepatitis AB vaccines in pregnant women. Am J Obstet Gynecol 2014, 210(561):e1-e6.
13. Moro P.L., Broder K., Zheteyeva Y., Revzina N., Tepper N., Kissin D., et al. Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. Am J Obstet Gynecol 2011, 205(473):e1-e9.
14. Zheteyeva Y.A., Moro P.L., Tepper N.K., Rasmussen S.A., Barash F.E., Revzina N.V., et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol 2012, 207(July (1)). 59.e1-59.e7.
15. Black S., Eskola J., Siegrist C.A., Halsey N., Macdonald N., Law B., et al. Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines. Lancet 2009, 374:2115-2122.
16. Dana A., Buchanan K.M., Goss M.A., Seminack M.M., Shields K.E., Korn S., et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009, 114(December (6)):1170-1178.
17. Goss M.A., Lievano F., Seminack M.M., Dana A. No adverse signals observed after exposure to human papillomavirus type 6/11/16/18 vaccine during pregnancy. Obstet Gynecol 2014, 123(May (5)):93S.
18. Garland S.M., Ault K.A., Gall S.A., Paavonen J., Sings H.L., Ciprero K.L., et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009, 114:1179-1188.
19. Dunne E.F., Markowitz L.E., Saraiya M., Stokley S., Middleman A., Unger E.R., Centers for Disease Control and Prevention (CDC), et al. CDC grand rounds: reducing the burden of HPV-Associated cancer and disease. MMWR Morb Mortal Wkly Rep 2014, 63(January (4)):69-72.